Outcomes of COVID‐19 in multiple myeloma patients treated with daratumumab

Abstract

Despite concerns about an increased risk of adverse outcomes following coronavirus disease (COVID‐19) in multiple myeloma patients treated with anti‐CD38 Abs, the impact of COVID‐19 on this group of patients is unclear. We tried to evaluate the clinical outcomes of these patients. We collected data from 1036 patients with multiple myeloma and enrolled 509 cases with COVID‐19. We divided enrolled patients into daratumumab or nondaratumumab cohorts based on whether they had received daratumumab‐based treatment within 6 months of COVID‐19 infection. We applied a propensity score matching method to reduce the bias of baseline characteristics, and then compared the incidence of adverse outcomes between these two cohorts. A total of 117 patients were enrolled in the daratumumab cohort, and 392 patients in the nondaratumumab cohort. After propensity score matching, 204 patients were matched. The proportions of patients who developed COVID‐19 pneumonia (59.8% vs. 34.3%, p < 0.001), were hospitalized (33.3% vs. 11.8%, p < 0.001) and developed severe disease (23.5% vs. 6.9%, p = 0.001) were higher in the matched daratumumab cohort. By multivariate analysis, daratumumab exposure was an independent risk factor for severe disease. An ECOG performance status >2 and history of chronic kidney disease were independent risk factors for COVID‐19‐related mortality among patients who received daratumumab‐based therapy. This study suggested that multiple myeloma patients exposed to daratumumab were at a higher risk of adverse outcomes from COVID‐19.